EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 December 2018
EMA/28227/2019
Human Medicines Evaluation Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
Sutent/ sunitinib	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s)in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):	
Name and address of the MAH:	Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles BELGIUM

Procedure	
Procedure number:	EMEA/H/C/000687/II/0070

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

-the development of this product has complied with all measures in the agreed paediatric investigation plan P/0147/2018. All studies in the agreed paediatric investigation plan P/0147/2018 were conducted after the entry into force of that Regulation.

-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0147/2018 is included in the technical dossier.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact